Implication of glycogen synthase kinase 3 in diabetes-associated islet inflammation

in Journal of Endocrinology

Correspondence should be addressed to J Movassat:
Restricted access

Islet inflammation is associated with defective β cell function and mass in type 2 diabetes (T2D). Glycogen synthase kinase 3 (GSK3) has been identified as an important regulator of inflammation in different diseased conditions. However, the role of GSK3 in islet inflammation in the context of diabetes remains unexplored. In this study, we investigated the direct implication of GSK3 in islet inflammation in vitro and tested the impact of GSK3 inhibition in vivo, on the reduction of islet inflammation, and the improvement of glucose metabolism in the Goto-Kakizaki (GK) rat, a spontaneous model of T2D. GK rats were chronically treated with infra-therapeutic doses of lithium, a widely used inhibitor of GSK3. We analyzed parameters of glucose homeostasis as well as islet inflammation and fibrosis in the endocrine pancreas. Ex vivo, we tested the impact of GSK3 inhibition on the autonomous inflammatory response of non-diabetic rat and human islets, exposed to a mix of pro-inflammatory cytokines to mimic an inflammatory environment. Treatment of young GK rats with lithium prevented the development of overt diabetes. Lithium treatment resulted in reduced expression of pro-inflammatory cytokines in the islets. It decreased islet fibrosis and partially restored the glucose-induced insulin secretion in GK rats. Studies in non-diabetic human and rat islets exposed to inflammatory environment revealed the direct implication of GSK3 in the islet autonomous inflammatory response. We show for the first time, the implication of GSK3 in islet inflammation and suggest this enzyme as a viable target to treat diabetes-associated inflammation.

Supplementary Materials

    • Supplementary Figure 1. LiCl treatment does not alter the vital parameters of Wistar and GK rats. Five weeks old male GK and Wistar rats were treated with lithium chloride (LiCl) for 6 weeks (GK/Li, n=30; Wistar/Li, n=6) or 11 weeks (GK/Li, n=10; Wistar/Li, n=6). (A) Food consumption and (B) water consumption were monitored in lithium treated and in age-matched respective controls rats (GK, n=40; Wistar, n=12). (C) The food intake was calculated as g (g body weight)-1 at 5 weeks of age in Wistar and GK rats. *, P <0.05. Results are expressed as means ±SEM. Unpaired student t test (C) was used for statistical analysis.
    • Supplementary Figure 2. Lithium phosphorylates and inhibits GSK3b. Five weeks old male GK were treated with lithium chloride (LiCl) for 6 weeks (GK n=5; GK/Li, n=6). GSK3β and phospho-Ser9-GSK3β protein levels were determined and quantified on total pancreas.
    • Supplementary Materials